The FDA announced a second tranche of Commissioner’s National Priority Vouchers (CNPVs), adding six more drugs that will be eligible for expedited review, and included high‑profile obesity candidates among the awardees. The list extension follows the administration’s effort to pair faster reviews with pricing agreements for certain weight‑loss medicines. Companies named in the round include developers of oral and injectable GLP‑1 and amylin pathway drugs; regulators said the vouchers aim to prioritize candidates aligned with U.S. public‑health priorities and domestic manufacturing goals. The program's expansion has immediate commercial and regulatory implications: voucher winners can shortcut review timetables, potentially accelerating approvals and launches, while also generating political and market debate over which products merit priority access.